Caitong International Asset Management’s Orchestra BioMed OBIO Stock Holding History

Caitong International Asset Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65	Buy	+15	New	+$61	﹤0.01%	2297

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Caitong International Asset Management's OBIO Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Orchestra BioMed (OBIO) in Q2 2026: 15 shares worth $65. The stake represents ﹤0.01% of the portfolio and ranks #2297 among its holdings.

77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

Caitong International Asset Management held 15 shares of Orchestra BioMed worth $65 as of Q2 2026.
Orchestra BioMed was a new Caitong International Asset Management position in Q2 2026.
Orchestra BioMed made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2297 holding.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.